TCRT — Alaunos Therapeutics Balance Sheet
0.000.00%
- $6.76m
- $2.61m
- $0.01m
Annual balance sheet for Alaunos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 79.7 | 115 | 76.1 | 39.1 | 6.06 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.33 | 4.67 | 1.11 | 0.004 | 0.001 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 105 | 131 | 78.8 | 53.8 | 8.26 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.38 | 14.9 | 15.4 | 10.6 | 0.002 |
Other Long Term Assets | |||||
Total Assets | 109 | 146 | 94.9 | 64.9 | 8.26 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 12.5 | 18.4 | 16 | 24.2 | 1.96 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 14.1 | 22.4 | 36.8 | 26.4 | 1.96 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 95 | 124 | 58.1 | 38.6 | 6.31 |
Total Liabilities & Shareholders' Equity | 109 | 146 | 94.9 | 64.9 | 8.26 |
Total Common Shares Outstanding |